申请人:ENANTA PHARMACEUTICALS, INC.
公开号:US20160289262A1
公开(公告)日:2016-10-06
The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof,
The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.